Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GV-JEV
- Development stage
- Preclinical
- Lead developer
- GreenVax
- Modality
- Vaccines & Immunotherapeutics
01
Overview
GV-JEV (also known as GEV-005) is an investigational inactivated vaccine being developed by GreenVax for the prevention of Japanese encephalitis. The vaccine is designed using GreenVax's proprietary B cell T cell Collaboration (BTC) platform, which utilizes epigallocatechin gallate (EGCG)—a natural green tea catechin—as an inactivating agent instead of traditional formalin. This approach aims to completely inactivate the Japanese encephalitis virus while minimizing damage to the antigen's structural integrity, thereby enhancing immunogenicity and safety. GV-JEV is currently in the basic research stage of development.
Beyond the preview
Go deeper on GV-JEV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GV-JEV.